Immunotherapy in Melanoma | Specialty

The Future of Driver Mutations in NSCLC

December 22nd 2016

Practical Experience With Dabrafenib/Trametinib in NCSLC

December 22nd 2016

Targeted Approaches in NSCLC: Lessons from Melanoma

December 22nd 2016

Patient Selection in BRAF-Mutant NSCLC

December 22nd 2016

The Evolving Mutational Landscape in NSCLC

December 22nd 2016

NSCLC: The BRAF/MEK Combination Safety Profile

December 22nd 2016

BRAF/MEK Efficacy in BRAF-mutant NSCLC

December 22nd 2016

Role of the MAP Kinase Pathway in NSCLC

December 22nd 2016

Outcomes With Chemotherapy in BRAF-Mutant NSCLC

December 22nd 2016

Understanding the BRAF-mutated Population in NSCLC

December 22nd 2016

Current Mutation Testing in Lung Cancer

December 22nd 2016

Dr. Pavlick on Immunotherapy Clinical Trials in Basal and Squamous Cell Carcinomas

December 20th 2016

Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma.

Dr. Luke on Challenges With Immunotherapy in Melanoma

December 20th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.

Stefani Spranger on Checkpoint Blockade Therapies in Melanoma

December 16th 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses immune checkpoint blockade therapies that are currently being used to treat patients with melanoma.

Dr. Hamid on Promising Phase III Trials in Melanoma

December 16th 2016

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses 2 exciting, ongoing phase III randomized trials in melanoma.

Dr. Long on Treating Melanoma With Dabrafenib Plus Trametinib

November 17th 2016

Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.

Sponsored Content: The Changing Paradigm of Cancer Research

November 14th 2016

Immuno-oncology is among the most discussed topics in cancer research, but many are unaware of the science behind this class of treatments. Learn how it works.

Dr. Amaria on Dabrafenib Plus Trametinib in Melanoma

November 10th 2016

Rodabe N. Amaria, MD, assistant professor Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of a recent trial testing neoadjuvant and adjuvant dabrafenib plus trametinib versus standard of care in high-risk resectable BRAF-mutant melanoma.

SD-101, Pembrolizumab Combo Well-Tolerated in Early-Stage Melanoma

November 10th 2016

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab (Keytruda) have demonstrated that the combination was well-tolerated with no dose-limiting toxicities.

Perioperative Dabrafenib/Trametinib Improves RFS in Stage III Melanoma

November 10th 2016

Treatment with the combination of dabrafenib and trametinib before and after surgery demonstrated a dramatic improvement in relapse-free survival compared with the standard of care for patients with stage IIIb/c or oligometastatic BRAF-mutant melanoma.